![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRP2BP |
Gene summary for LRP2BP |
![]() |
Gene information | Species | Human | Gene symbol | LRP2BP | Gene ID | 55805 |
Gene name | LRP2 binding protein | |
Gene Alias | LRP2BP | |
Cytomap | 4q35.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9P2M1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55805 | LRP2BP | HCC1 | Human | Liver | HCC | 1.70e-06 | 9.83e-01 | 0.5336 |
55805 | LRP2BP | HCC2 | Human | Liver | HCC | 1.54e-16 | 1.55e+00 | 0.5341 |
55805 | LRP2BP | HCC5 | Human | Liver | HCC | 2.64e-03 | 6.85e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRP2BP | deletion | Frame_Shift_Del | novel | c.771delN | p.Lys257AsnfsTer24 | p.K257Nfs*24 | Q9P2M1 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
LRP2BP | deletion | Frame_Shift_Del | c.441delN | p.Gly148ValfsTer26 | p.G148Vfs*26 | Q9P2M1 | protein_coding | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
LRP2BP | SNV | Missense_Mutation | novel | c.914N>T | p.Arg305Met | p.R305M | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRP2BP | SNV | Missense_Mutation | novel | c.579N>T | p.Lys193Asn | p.K193N | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRP2BP | SNV | Missense_Mutation | novel | c.72N>A | p.Asn24Lys | p.N24K | Q9P2M1 | protein_coding | tolerated(0.79) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRP2BP | SNV | Missense_Mutation | c.357N>C | p.Lys119Asn | p.K119N | Q9P2M1 | protein_coding | deleterious(0.05) | benign(0.31) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LRP2BP | SNV | Missense_Mutation | c.135N>T | p.Lys45Asn | p.K45N | Q9P2M1 | protein_coding | deleterious(0.01) | benign(0.046) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRP2BP | SNV | Missense_Mutation | c.884G>A | p.Gly295Asp | p.G295D | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A064-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRP2BP | SNV | Missense_Mutation | novel | c.643C>T | p.Leu215Phe | p.L215F | Q9P2M1 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRP2BP | SNV | Missense_Mutation | c.158N>T | p.Arg53Ile | p.R53I | Q9P2M1 | protein_coding | deleterious(0) | possibly_damaging(0.694) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |